IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Starting soon · Early Phase 1

Conditions studied: Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL)

In brief

This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.

Key facts

Study ID

NCT07185490

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

40

Starts

2026-02-15

Expected to finish

2029-08-15

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years, any gender.
• Diagnosis of multiple myeloma (MM) per International Myeloma Working Group (IMWG) diagnostic criteria.
• Prior therapy requirements:
• MM patients: ≥3 prior lines of therapy, including:
• 1 proteasome inhibitor (PI)
• 1 immunomodulatory drug (IMiD)
• 1 anti-CD38 monoclonal antibody Exception: No minimum line requirement for subjects refractory to PIs, IMiDs, and anti-CD38 therapy.
• Primary plasma cell leukemia (pPCL): ≥1 prior line including ≥1 PI and ≥1 IMiD.
• Documented disease progression during/within 12 months after last anti-myeloma therapy (exemption: No 12-month requirement if last line was CAR-T).
• Measurable disease at screening (≥1 of the following):
• Serum M-protein:
• IgG ≥10 g/L IgA/IgD/IgE/IgM ≥5 g/L Urine M-protein ≥200 mg/24h Serum free light chains (FLC): Involved FLC ≥100 mg/L with abnormal κ/λ ratio Bone marrow plasma cells ≥30% (if no measurable M-protein/FLC).
• ECOG performance status 0-1.
• Life expectancy ≥12 weeks.
• Adequate organ function (all lab values within 7 days prior to enrollment):
• Hematology:
• Absolute neutrophil count (ANC) ≥1×10⁹/L (allowed: growth factor support, but none within 7 days) Absolute lymphocyte count (ALC) ≥0.3×10⁹/L Platelets ≥50×10⁹/L (no transfusion within 7 days) Hemoglobin ≥60 g/L (no RBC transfusion within 7 days; erythropoietin allowed)
• Liver:
• ALT/AST ≤2.5×ULN Total bilirubin ≤1.5×ULN Renal: Calculated CrCl ≥40 mL/min (Cockcroft-Gault)
• Coagulation:
• Fibrinogen ≥1.0 g/L aPTT/PT ≤1.5×ULN Pulmonary: SpO₂ >91% (room air) Cardiac: LVEF ≥50% (echocardiography).
• Contraception: Subjects/partners must use effective contraception from consent through 1 year post CAR-T infusion (excluded: calendar method).
• Signed informed consent approved by the Ethics Committee prior to screening.

You may not qualify if…

• Active graft-versus-host disease (GVHD) or requiring long-term immunosuppressive therapy.
• Prior hematopoietic stem cell transplantation (HSCT):
• Autologous HSCT (Auto-HSCT) within 12 weeks before apheresis,
• ≥2 prior Auto-HSCTs, Any prior allogeneic HSCT (Allo-HSCT).
• Prior cell therapy targeting plasma cells within 3 months before apheresis, or detectable residual cellular therapy products in peripheral blood.
• Recent anti-myeloma therapies (relative to apheresis):
• Monoclonal antibody treatment within 21 days, Cytotoxic chemotherapy or proteasome inhibitors within 14 days, Immunomodulatory drugs within 7 days, Other anti-tumor therapies within 14 days or 5 half-lives (whichever is shorter).
• Chronic corticosteroid use (>20 mg/day prednisone or equivalent), except for physiologic replacement, topical, or inhaled use.
• Uncontrolled hypertension despite medication.
• Severe cardiac disease, including:
• Unstable angina, Myocardial infarction (within 6 months before screening), Congestive heart failure (NYHA Class ≥III), Severe arrhythmias.
• Unstable systemic illnesses per investigator's judgment (e.g., severe hepatic, renal, or metabolic disorders requiring medication).
• Other malignancies within 5 years, excluding:
• Carcinoma in situ of the cervix, Basal/squamous cell skin cancer, Localized prostate cancer post-radical resection, Ductal breast carcinoma in situ post-resection.
• History of solid organ transplantation.
• Suspected or confirmed CNS involvement by plasma cell neoplasms.
• Major surgery within 2 weeks before apheresis or planned within 2 weeks post-treatment (allowed: minor procedures under local anesthesia).
• Investigational drugs within 1 month before apheresis.
• Uncontrolled active infections:
• Persistent symptoms despite appropriate therapy, Requiring IV antimicrobials at screening.
• Viral infections:
• HBV: HBsAg(+) or HBcAb(+) with detectable HBV DNA, HCV: HCV Ab(+) with detectable HCV RNA, HIV Ab(+), CMV DNA(+), Syphilis: TRUST(+) and TPPA(+).
• Pregnancy or lactation.
• Psychiatric disorders, cognitive impairment, or active CNS diseases.
• Other conditions deemed ineligible by the investigator.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.